Atea Pharmaceuticals Stock Current Valuation
| AVIR Stock | USD 3.77 0.22 6.20% |
Valuation analysis of Atea Pharmaceuticals helps investors to measure Atea Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of 10/17/2024, Enterprise Value Over EBITDA is likely to drop to -0.99. In addition to that, Enterprise Value Multiple is likely to drop to -0.99. Fundamental drivers impacting Atea Pharmaceuticals' valuation include:
Price Book 0.629 | Enterprise Value -200.5 M | Enterprise Value Ebitda (260.47) | Price Sales 1.9026 | Enterprise Value Revenue 58.974 |
Fairly Valued
Today
Please note that Atea Pharmaceuticals' price fluctuation is moderately volatile at this time. Calculation of the real value of Atea Pharmaceuticals is based on 3 months time horizon. Increasing Atea Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Atea stock is determined by what a typical buyer is willing to pay for full or partial control of Atea Pharmaceuticals. Since Atea Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Atea Stock. However, Atea Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.77 | Real 3.77 | Target 4.0 | Hype 3.81 | Naive 3.9 |
The intrinsic value of Atea Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Atea Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Atea Pharmaceuticals helps investors to forecast how Atea stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Atea Pharmaceuticals more accurately as focusing exclusively on Atea Pharmaceuticals' fundamentals will not take into account other important factors: Atea Pharmaceuticals Company Current Valuation Analysis
Atea Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Atea Pharmaceuticals Current Valuation | (200.49 M) |
Most of Atea Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Atea Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Atea Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Atea Pharmaceuticals is extremely important. It helps to project a fair market value of Atea Stock properly, considering its historical fundamentals such as Current Valuation. Since Atea Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Atea Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Atea Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Atea Pharmaceuticals has a Current Valuation of (200.49 Million). This is 101.4% lower than that of the Pharmaceuticals sector and 104.32% lower than that of the Health Care industry. The current valuation for all United States stocks is 101.21% higher than that of the company.
Atea Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atea Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atea Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Atea Pharmaceuticals by comparing valuation metrics of similar companies.Atea Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Atea Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Atea Pharmaceuticals from analyzing Atea Pharmaceuticals' financial statements. These drivers represent accounts that assess Atea Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Atea Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.5B | 3.4B | 740.4M | 400.4M | 460.5M | 437.4M | |
| Enterprise Value | 2.5B | 2.6B | (23.8M) | (243.2M) | (279.7M) | (265.7M) |
Atea Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Atea Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Atea Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Atea Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | (200.49 M) | ||||
| Shares Outstanding | 84.42 M | ||||
| Shares Owned By Insiders | 9.67 % | ||||
| Shares Owned By Institutions | 69.60 % | ||||
| Number Of Shares Shorted | 2.78 M | ||||
| Price To Earning | 15.03 X | ||||
| Price To Book | 0.63 X | ||||
| Price To Sales | 1.90 X | ||||
| Gross Profit | (81.94 M) | ||||
| EBITDA | (119.59 M) | ||||
| Net Income | (135.96 M) | ||||
| Cash And Equivalents | 684.48 M | ||||
| Cash Per Share | 8.22 X | ||||
| Total Debt | 2.4 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 27.46 X | ||||
| Book Value Per Share | 5.64 X | ||||
| Cash Flow From Operations | (85.39 M) | ||||
| Short Ratio | 11.01 X | ||||
| Earnings Per Share | (2.10) X | ||||
| Target Price | 6.88 | ||||
| Number Of Employees | 75 | ||||
| Beta | 0.17 | ||||
| Market Capitalization | 320.06 M | ||||
| Total Asset | 594.97 M | ||||
| Retained Earnings | (195.84 M) | ||||
| Working Capital | 558.08 M | ||||
| Current Asset | 97.88 M | ||||
| Current Liabilities | 6.25 M | ||||
| Net Asset | 594.97 M |
About Atea Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atea Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atea Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atea Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Atea Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Atea Stock
| 0.33 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.
The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.